Positive Phase III data on Baxalta's investigational Von Willebrand disease product BAX 111

Baxalta (NYSE: BXLT), a recent spin-out form Baxter International, has announced the publication of positive pivotal Phase III data for BAX 111 in Blood, the journal of the American Society of Hematology.

The data showed that 100% of the patients treated with BAX 111, a highly purified recombinant von Willebrand factor (rVWF) candidate, achieved success in the management of bleeding episodes. BAX 111 is currently under review by the US Food and Drug Administration. If approved, BAX 111 would become the first recombinant replacement treatment for managing bleeding episodes for von Willebrand patients.

Potential to transform the standard of care